Auriga Partners leads €7m series-A for Nextbiotix
French VC Auriga Partners has led a €7m series-A funding round for Nextbiotix, a microbiome biotech company developing biotherapeutics to treat inflammatory bowel diseases.
Early-stage private equity firm Sofimac Innovation, startup fund Cap Innov'Est, Inra, and pharmaceutical company Biocodex, also participated in the funding round.
The fresh funding will be used to support research to bring its new class of medicine – live biotherapeutics – to patients.
Company
Established in 2016 and headquartered in Dijon, Nextbiotix was founded by scientists working in the field of gut microbiota. The company's vision is to bring gut microbiota back into therapeutic use through a bacterium called faecalibacterium prausnitzii.
People
Nextbiotix – Benjamin Hadida (co-founder, CEO).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds









